from 21st Century Wire:
Were the COVID-19 vaccines part of dual-use “Biodefence Security Covered Countermeasures,” and were they developed by the US Department of Defense prior the ‘global pandemic’?
21st Century Wire
In analyzing the timeline of the COVID-19 pandemic response and the subsequent vaccine roll-out, the structure they have put in place is nothing short of amazing. Governments have erected an incredible shield – protected behind a legal framework which they have carefully crafted over the years, creating revolving doors and loopholes for themselves to side-step all public health regulatory measures by declaring a “Public Health Emergency” and the subsequent Emergency Use Authorization (EUA) it triggers.
TRUTH LIVES on at https://sgtreport.tv/
In hindsight, we now know that COVID-19 wasn’t a public health emergency, so why did governments go through so much trouble to protect themselves from liability, and gamble with the health and well-being of entire populations? This has never happened before in human history. Is their more to this than meet the eyes?
COVID-19 Response and Its Security Covered Countermeasures
As a result of few confirmed cases of 2019 ‘novel’ coronavirus (2019-nCoV), on 31 January, 2020, Alex M. Azar II, Secretary of Health and Human Services (HHS), pursuant to the authority vested in him under section 319 of the Public Health Service Act, determined that a public health emergency existed and had existed since 27 January, 2020 in the United States of America.
Many of us have vivid memories regarding Trump’s announcement and the subsequent launch of his ‘Operation Warp Speed’ vaccine task force in response to the coronavirus outbreak.
Coronavirus outbreak: Trump announces launch of ‘Operation Warp Speed’ vaccine task force:
As of 30 January, 2021, five of the six Operation Warp Speed (OWS) vaccine candidates had entered Phase 3 clinical trials, two of which were Moderna’s and Pfizer/BioNTech’s vaccines. We were led to believe that they had received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). For vaccines that received the EUA, additional data on vaccine effectiveness were generated from further follow-up of participants in clinical trials already underway before the EUA was issued.
The questions we will be addressing in this article are essential and crucial to understand the FDA’s role during the COVID-19 pandemic response, and to establish if indeed the FDA was legally in charge of the regulatory processes including the assessment of the clinical data from the vaccine manufacturers.
Was FDA mandate adapted to ensure a strict independent review of the clinical data in the context of an Emergency Use Authorization, and was current Good Manufacturing Practice (cGMP) respected? Both questions need to be answered, as they touch upon vital measures and protocols which are expected to be in place to ensure the safety and efficacy of a new vaccine to be deployed within the American population.
FDA – The Regulatory Smoke Screen
Firstly, it’s important to identify who were the key players behind the COVID-19 pandemic response.
“Operation Warp Speed” was operating largely independently of the existing White House coronavirus task force, which we now know at some stage shifted its focus toward vaccine development.
According to the White House statement, Colonel Deborah Birx was detailed to the office of the Vice President and reported directly to Mike Pence. She was fully supported by the National Security Council (NSC) and joined the task force led by Health and Human Services (HHS) Secretary Alex Azar.
Here is a list of some of the key operatives of the Operation Warp Speed.
We could spend hours exposing the conflicts of interest many of these operatives have with Big Pharma, but for now let’s focus on Colonel Deborah Birx, President Donald Trump’s COVID-19 coordinator, and provide you with some interesting comments made by Dr Stephen M. Hahn, MD, Commissioner of U.S. Food and Drug Administration during an interview with the Reagan-Udall Foundation, and the American Medical Association (AMA) President Susan R. Bailey, MD where he outlined some aspects of the FDA’s response during the pandemic.
Everything about Colonel Deborah Birx (source)
Birx began her career with the Department of Defense, serving at Walter Reed Army Medical Center and rising to the rank of colonel while serving as the director of the U.S. Military’s HIV Research Program.
She was a strategic OWS asset, acting as what we could call “The Bridge” between the NSC statutory members, the HSS and the US DoD. Her mandate was perhaps one the of the most strategic within the federal government and by taking the time to review her career, we can better understand why she was picked by the DoD and the NSC to be the lead interface with the HHS and its various partner agencies.
Birx served as director of the Centers for Disease Control’s (CDC) Division of Global HIV/AIDS from 2005 to 2014 and brought a wealth of experience in infectious disease, immunologic, vaccine research and inter-agency coordinating capacity to address the challenges faced by both Operation Warp Speed and the National Security Council who were not shy to characterize the FDA as a ‘scientific advisory body’ rather than a regulator.
Birx became an ambassador for Global Health Diplomacy in April 2014, where she was the US government’s leader for combating AIDS globally, and she was expected to bring that expertise to the coronavirus response in 2020.
Power in the Pandemic
A “working organization chart” obtained by the journal Science, shows Col. Deborah Birx’s central roles in the federal COVID-19 response. She coordinated the White House Coronavirus Task Force (WHCTF) and co-chairs two of its three divisions: the Unified Coordination Group, which manages the response from the HHS and DoD, and Operation Warp Speed, whose task was to develop vaccines in cooperation with several agencies. The Physician Advisory Group had only an advisory role.